Anixa Biosciences is trading 9.33% up at $3.75 after positive breast-cancer vaccine Phase 1 results and encouraging ovarian-cancer CAR-T survival observations.
- The August 18 announcement included plans to present at the H.C. Wainwright conference.
- Company-specific news likely supports today’s move, while the broader biotechnology sector is also strengthening.
- No separate August 19 announcement or explicit trading attribution was identified.